DAYTON, Ohio–(BUSINESS WIRE)–MedsEngine LLC, a provider of chronic disease management software, presented its findings on blood pressure control to the European Society of Hypertension in Milan, Italy, May 23-26, 2025. The findings showed that users of the MedsEngine Hypertension module were able to achieve high BP control rates, to a goal of <140/90, in less than two office visits.
These results build on earlier presentations at the European Society of Cardiology Congress in 2023 and 2024, where MedsEngine reported sustained blood pressure control rates of 92% over a 10-year period. Further analysis linked these outcomes to a significant reduction in heart attacks and cerebrovascular events, underscoring the long-term clinical impact of optimized hypertension management.
The MedsEngine platform enables physicians and advanced practice providers to rapidly evaluate patients and generate personalized, evidence-based medication recommendations in just minutes—transforming the standard of care for hypertension.
“Our data from over 14,000 patients across two major medical groups show that personalized, technology-driven medication recommendations dramatically reduce the risk of strokes and heart attacks and improve patient understanding and adherence,” said Dr. Doug Romer, Chief Medical Officer at MedsEngine. “This level of precision and efficiency illustrates the value of using technology to control chronic diseases.”
About MedsEngine
MedsEngine develops EHR-integrated clinical decision support applications that generate real-time, personalized, evidence-based medication recommendations for hypertension, cholesterol management, type 2 diabetes, and heart failure. Medical groups utilizing MedsEngine have seen nation-leading hypertension control, higher HEDIS scores and Star ratings, lower medical costs, standardized care across all providers, improved office workflow and greater patient understanding and satisfaction.
Contacts
NEW YORK CITY, NY / ACCESS Newswire / January 10, 2026 / The phrase best…
CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…
Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…
Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…
Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…
Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…
